Introduction
============

Recently, several reports demonstrated that aflatoxin B~1~ (AFB~1~) is probably the most common researched mycotoxin in the world ([@B37]; [@B3]). Many *Aspergillus* species such as *Aspergillus flavus* and *Aspergillus parasiticus* produce AFB~1~ ([@B42]). It is considered to be one of the most harmful and potent aflatoxins among all other known mycotoxins ([@B16]). AFB~1~ causes many adverse effects such as mutagenicity, carcinogenicity, hepatotoxicity, and immunotoxicity in humans, poultry and in many other animal species ([@B54]; [@B28]). AFB~1~ has the ability to affect more than one system at a time and cause serious alterations in the normal homeostasis of the affected organism ([@B16]; [@B23]). It has been placed in Group-1 human carcinogen by the International Agency for Research on Cancer (IARC) ([@B61]). AFB~1~ leads to carcinogenicity in humans by p53 gene mutation at codon 249 and formation of DNA adducts ([@B6], [@B5]). Previous reports showed that the liver is the major target organ of AFB~1~, as the liver plays a crucial role in drug or toxin metabolism and detoxification in the body ([@B21]; [@B47]). AFB~1~ causes liver toxicity including infiltration of mononuclear and heterophilic cells and proliferation of bile duct along with changes in liver morphology, such as increase in liver weight, enlargement, congestion, necrosis, and pallor discoloration ([@B44]; [@B24]), but the susceptibility of a species to AFB~1~ depends on various factors such as type of breed, immunity and nutritional status, age, sex, dose, length of exposure to AFB~1~, and managemental conditions ([@B48]).

The use of naturally occurring phytochemicals to combat human diseases and prevent toxicity is of growing scientific and public interest due to their potential therapeutic uses ([@B51]). Curcumin is a polyphenol commonly composed of three types of curcuminoids, bisdemethoxycurcumin, demethoxycurcumin, and diferuloylmethane, derived from the rhizome of *Curcuma longa* (Common name: turmeric) famous for its pharmacological and therapeutic properties ([@B7]). Several reports have documented the anti-inflammatory, anti-oxidative, anti-cancerous, and potent chemotherapeutic properties of curcumin ([@B4]; [@B26]; [@B35]; [@B36]; [@B46]). It has been proved earlier that curcumin is effective against AFB~1~-induced oxidative stress ([@B20]; [@B15]). Moreover, previous studies demonstrated that curcumin modulated phase-I enzymes activity and has the potential to control AFB~1~-induced carcinogenesis and toxic effects ([@B17]; [@B8]; [@B43]). Cytochrome p450 (phase-I) enzymes are responsible for the biotransformation of AFB~1~ into its harmful metabolites ([@B59]). Earlier reports showed that several CYP enzymes (CYP1A1, CYP1A2, CYP1A5, CYP2A6, CYP3A37, and CYP3A4) were involved in bioactivation of AFB~1~ into its harmful electrophilic metabolite aflatoxin-8,9-epoxide (AFBO) and to AFM~1~, AFP~1~, AFQ~1~, etc. ([@B22]). AFBO, the most potent metabolite may quickly react with DNA to form DNA adducts or cause mutations ([@B6]), or conjugated with phase-II enzymes such as glutathione S-transferases (GST) ([@B27]). Importantly, the sensitivity of a species to AFB~1~ is not only related to AFB~1~ bioactivation via CYP enzymes but also related to detoxification enzymes (phase-II enzymes) ([@B30]). It is well known that the transcription factor nuclear factor-erythroid-2-related factor 2 (Nrf2) plays a crucial role in regulating several pathways, including drug metabolism, antioxidant, and detoxification such as phase-II enzymes like superoxide dismutase, catalase, NAD(P)H:quinine oxidoreductase-1, uridine 5-diphospho (UDP) glucuronosyltransferase, heme oxygenase-1 (HO-1), glutathione *S*-transferase, glutathione peroxidase (GPx), thioredoxin, and uridine 5-diphospho (UDP)-glucuronosyltransferase ([@B34]). Besides, [@B52] studies demonstrated that up-regulation of Nrf2-pathway and its downstream genes (GSTs) prevented chemical carcinogenesis . Moreover, Nrf2 plays an important cytoprotective role in disease prevention, especially at the initiation stage of cancer development ([@B31]). Thus, inhibition of phase-I enzymes (involved in AFB~1~-bioactivation) and activation of Nrf2-pathway and its downstream genes (related to AFB~1~-detoxification) could be a novel pharmacological approach for the prevention of AFB~1~-induced liver injury and oxidative stress in broilers. The present study was designed to shed light on the multi-target effects of curcumin through inhibition of phase-I enzymes, and activation of Nrf2 as well as phase-II enzymes against AFB~1~-induced liver injury and ameliorating oxidative stress in Arbor Acres broiler liver. The study contributed to provide a biochemical basis for the supplementation of curcumin in broiler's diet along with its chemopreventive action against AFB~1~-induced liver injury.

Materials and Methods {#s1}
=====================

Ethics Statement
----------------

All the experiments were performed according to animal ethics guidelines and approved protocols of the Harbin Veterinary Research Institute of the Chinese Academy of Agricultural Sciences \[SYXK (Hei) 2012-2067\].

Chemicals and Reagents
----------------------

Methanol, ethanol (99.0%), isopropanol, chloroform, and glycine were bought from Tian Li Company Ltd. (Tianjin, China). AFB~1~ (purity ≥ 99.0%) was obtained from Sigma-Aldrich (St. Louis, United States). Curcumin (2.5%) was bought from Weisheng Long Chemical Company Ltd. (China). Hematoxylin and eosin were bought from Nanjing chemical reagent factory (China).

Experimental Chickens, Diets, and Sample Collection
---------------------------------------------------

One-day-old healthy Arbor Acres broiler chickens were bought from Yi Nong commercial hatchery (Registration number; 230108799294096, Heilongjiang, China). The broilers were divided in four groups (15 chicks/group) and assigned to different cages. Chickens were provided with 12 h light and 12 h dark cycle and fed *ad libitum* for 28 days. Four dietary groups were: (G1) control group; fed only basal diet, (G2) curcumin control group: basal diet incorporated with 450 mg curcumin/kg feed; (G3) AFB~1~ group: basal diet contaminated with 5.0 mg AFB~1~/kg feed; and (G4) curcumin+AFB~1~ group: basal diet incorporated with 5.0 mg AFB~1~ and 450 mg curcumin/kg feed. After 28 days, chickens were first weighed, euthanized with sodium pentobarbital, and sacrificed in an antiseptic environment. Liver was collected, weighed and stored at -80°C for further analysis.

Serum Biochemical Analysis
--------------------------

Serum biochemical markers were measured to evaluate liver toxicity. 5 ml blood sample was collected from the vein wing before slaughtering of chickens. Serum was separated after centrifugation at 3000 *g* for 1.5 h and biochemical analysis was carried out at the same time. Serum samples were analyzed for alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and gamma-glutamyl transferase (GGT) activities in an automatic biochemical analyzer (Model 7080, Japan Hitachi Limited).

Histological Observation
------------------------

Liver morphology was assessed by histopathological examination. Fresh liver tissue pieces were stained with hematoxylin and eosin (HE) as previously described ([@B57]). In brief, liver sections (1 cm × 1 cm) were fixed in 10% formalin for 24 h. The fixed liver tissues were embedded in paraffin after processed through a series of graded ethanol and dimethyl benzene. 4-μm tissue sections were mounted on glass slides, and finally stained with HE dye for microscopic examination (Light microscope; Nikon E100, 40× magnification).

Measurement of Antioxidant Enzyme Activities
--------------------------------------------

A piece of fresh liver tissue (0.4--0.5 g) was immediately taken out after slaughtering and chilled in 0.85% NaCl at 0°C. It was then dried and homogenized as previously described ([@B53]). The homogenized solution was then centrifuged (12,000 ×*g* for 15 min) at 4°C and the supernatants were analyzed for antioxidant activity. All the kits were bought from Nanjing Jiancheng Bioengineering Factory (China). GSH-Px (Glutathione peroxidase, kit; A005), SOD (Superoxide dismutase, kit; A001-1) and MDA (Malonaldehyde, kit; A003-1) activities were measured in the supernatant according to the instructions of the kit.

RNA Extraction and Real-Time Quantitative Polymerase Chain Reaction (qPCR)
--------------------------------------------------------------------------

TRIzol (Invitrogen Inc., Carlsbad, CA) reagent was used to isolate total RNA ([@B11]). RNA quality was verified by measuring the 260/280 ratio ([@B56]). Toyobo first strand cDNA synthesis kit (Osaka, Japan) was used for the synthesis of cDNA. The target genes and β-actin loading control gene specific primers are given in **Table [1](#T1){ref-type="table"}**. The kit bought from Toyobo Company Ltd. (Japan) was utilized for RT-PCR reaction in a Roche LightCycle instrument (Shanghai, China). The data were analyzed according to 2^-ΔΔC~t~^ method ([@B38]).

###### 

Primers used for quantitative real-time PCR.

  Accession no.    Target gene   Primer    Sequence (5′--3′)       Length (bp)
  ---------------- ------------- --------- ----------------------- -------------
  NM_205147.1      CYP1A1        Forward   GAAGGGACCGAAGTGAACAA    115
                                 Reverse   TGGACAGGAAAAGGAACACC    
  NM_205146.2      CYP1A2        Forward   CATGTACCTTGTGACGCAGC    158
                                 Reverse   CAAATTGCCAGGTCGGAACC    
  KX687985.1       CYP2A6        Forward   CTGCAGAGAATGGCATGAAG    110
                                 Reverse   CCTGCAAGACTGCAAGGAA     
  NM_001329508.1   CYP3A4        Forward   AGTGGAGTTCAATGGGGTGA    160
                                 Reverse   CAGGAAGGTGTAGGGGTCAA    
  NM_205117.1      Nrf2          Forward   GATGTCACCCTGCCCTTAGA    124
                                 Reverse   TCGTTCCATTTGTTCCTTCTG   
  NM_001001777.1                 Forward   AGACCAGAGCCATCCTCAAC    
                   GSTA3,        Reverse   TGCCAGTCCTTCCACATACA    101
  NM_205090.1                    Forward   CCCAACCTGCCCTATCTCAT    
                   GSTM2         Reverse   CTGCTTCTCCACCTCCGTCT    114
  X00182.1                       Forward   TGAAGCCCAGAGCAAAAGAG    
                   β-actin       Reverse   TGCTCCTCAGGGCTACTCTC    135
                                                                   

Western Blot Analysis
---------------------

Western blotting was performed as described previously ([@B39]). In brief, fresh liver tissues were homogenized in RIPA and PMSF. 5 × SDS-PAGE loading buffer was added, followed by protein degeneration via boiling for 5 min. The loaded protein were separated by 10 or 12% SDS-PAGE, and transferred to nitrocellulose membrane (NC). The membranes were incubated for 1 h in non-fat dry milk in TBST. CYP1A1 (1:500 diluted, Sangon Biotech. Shanghai, China), CYP1A2 (1:400 diluted, Sangon Biotech, Shanghai, China), CYP3A4 (1:200 diluted, Sangon biotech. Shanghai, China), CYP2A6 (1:200 diluted, ImmunoWay Biotechnology Company, Suzhou, China), Nrf2 (1:500 diluted, Wanleibio Co., Ltd., Harbin, China), GSTA3, (1:200 diluted, Life Span Biosciences, Inc., Shanghai, China), GSTM2 (1:800 diluted, BBI Life Sciences, Canada), and β-actin (1:1000 diluted, Applied Biological Materials Inc., Canada) or GAPDH (1:100 diluted, Applied Biological Materials Inc., Canada) protein was detected using specific primary antibodies incubated overnight at 4°C. Secondary anti-mouse or anti-rabbit horseradish peroxidase conjugated IgG was used for 1 h, and immune-complexes were detected using enhanced chemiluminescence (ECL) detection. Signals were visualized on a computer using Image J software (National Institute of Health, United States).

Statistical Analysis
--------------------

The data significance were analyzed by one way ANOVA followed by LSD test using the statistical package for social science (SPSS, version 21.0), and *p* \< 0.05 was considered statistically significant. The experiments were performed at least three times unless otherwise mentioned. The data are represented as means ± standard errors. GraphPad Prism (Version 6.01) was used to draw all the graphs with standard error bars.

Results
=======

Curcumin Prevented AFB~1~-Induced Liver Injury
----------------------------------------------

Liver sections from control group (**Figure [1](#F1){ref-type="fig"}**; G1) and curcumin control group (**Figure [1](#F1){ref-type="fig"}**; G2) showed normal morphology. Dietary AFB~1~ induced severe liver injury (**Figure [1](#F1){ref-type="fig"}**; G3) compared to control and curcumin control group. Severe to moderate lesions such as hepatic granular degeneration, lymphocyte infiltration, and hepatic steatosis were observed in AFB~1~-fed group. The supplementation of curcumin in the diet partially ameliorated AFB~1~-induced hepatic lesions (**Figure [1](#F1){ref-type="fig"}**; G4). These results confirmed the preventive effects of curcumin against AFB~1~-induced liver injury.

![Chicken liver photomicrographs of hematoxylin and eosin-stained liver sections observed under light microscope (40X magnification), where n = 3 (H&E, scale bar = 20 μm). Treatments represented as **(G1)** control group; fed only basal diet, **(G2)** curcumin control group; basal diet + 450 mg curcumin/kg feed, **(G3)** AFB~1~ group; basal diet + 5.0 mg AFB~1~/kg feed, and **(G4)** curcumin+AFB~1~ group; basal diet + 5.0 mg AFB~1~ + 450 mg curcumin/kg feed. Yellow arrow, hepatic steatosis; red arrow, lymphocyte infiltration; and green arrow, hepatic granular degeneration.](fphar-09-00554-g001){#F1}

Effect of Curcumin and AFB~1~ on Serum Biochemical Parameters and Body and Liver Weight
---------------------------------------------------------------------------------------

Serum biochemical parameters (ALP, ALT, AST, and GGT level) are represented in **Table [2](#T2){ref-type="table"}**. Compared to control group (**Table [2](#T2){ref-type="table"}**; G1), AFB~1~ supplemented diet (**Table [2](#T2){ref-type="table"}**; G3) significantly (*p* \< 0.05) affected serum ALP, ALT, AST, and GGT level, While compared to curcumin control group (**Table [2](#T2){ref-type="table"}**; G2), AFB~1~-induce increase in ALT, ALP, and AST level is not statistically significant (*p* \> 0.05) except GGT level (*p* \< 0.05) (**Table [2](#T2){ref-type="table"}**; G3). However, curcumin supplementation in the diet prevented AFB~1~-induced changes in serum biochemical parameters (**Table [2](#T2){ref-type="table"}**; G4). The changes in serum biochemical parameters were inconsistent with the liver histological analysis (**Figure [1](#F1){ref-type="fig"}**). In addition, body weight and liver weight were recorded to study the changes in phenotypic effects (**Table [2](#T2){ref-type="table"}**). Notably, compared to control (**Table [2](#T2){ref-type="table"}**; G1) and curcumin control group (**Table [2](#T2){ref-type="table"}**; G2), body weight significantly (*p* \< 0.05) decreased in AFB~1~-fed group (**Table [2](#T2){ref-type="table"}**; G3). Moreover, liver weight significantly (*p* \< 0.05) decreased in AFB~1~-fed group. However, the supplementation of dietary curcumin (**Table [2](#T2){ref-type="table"}**; G4) reversed AFB~1~-induced changes in body and liver weight significantly (*p* \< 0.05).

###### 

Effect of curcumin and AFB~1~ on serum biochemical parameters, liver weight, and body weight of chickens.

  Name Groups   ALP (IU/L)             ALT (IU/L)         AST (IU/L)          GGT (IU/L)           Liver weight (g/bird)   Body weight (g/bird)
  ------------- ---------------------- ------------------ ------------------- -------------------- ----------------------- -----------------------
  G1            1725.00 ± 13.75        1.25 ± 0.03        209.53 ± 1.54       21.00 ± 0.14         21.37 ± 1.38            991.58 ± 19.73
  G2            1703.67 ± 14.27        1.50 ± 0.04        219.50 ± 1.37       22.00 ± 0.13         17.32 ± 0.86            873.36 ± 12.92^∗^
  G3            2446.33 ± 14.3^∗^      3.75 ± 0.06^∗^     262.0 ± 1.16^∗^     35.00 ± 0.25^∗,∗∗^   28.49 ± 1.74^∗∗^        608.00 ± 21.43^∗,∗∗^
  G4            1540.50 ± 28.73^∗∗∗^   2.00 ± 0.02^∗∗∗^   196.5 ± 1.78^∗∗∗^   15.33 ± 0.19^∗∗∗^    20.03 ± 0.63^∗∗∗^       823.00 ± 16.02^∗,∗∗∗^
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Curcumin Attenuated AFB~1~-Induced Oxidative Stress
---------------------------------------------------

After 28 days, the hepatic antioxidant parameters were significantly (*p* \< 0.05) altered by dietary AFB~1~ (**Figure [2](#F2){ref-type="fig"}**). Compared to control group (**Figure [2](#F2){ref-type="fig"}**; G1), GSH-Px and SOD activity were significantly (*p* \< 0.05) decreased while MDA activity was significantly (*p* \< 0.05) enhanced in AFB~1~-fed group (**Figure [2](#F2){ref-type="fig"}**; G3). The addition of curcumin alone (**Figure [2](#F2){ref-type="fig"}**; G2) increased GSH-Px activity significantly (*p* \< 0.05) but not significantly affected SOD and MDA activity. Importantly, dietary curcumin (**Figure [2](#F2){ref-type="fig"}**; G4) significantly (*p* \< 0.05) reversed AFB~1~-induced changes in antioxidant parameters. It is obvious from the results that curcumin effectively ameliorated AFB~1~-induced stress in broiler liver.

![It represents anti-oxidant activities of GSH-Px activity, SOD activity, and MDA activity. The values are represented as mean ± SE (*n* = 5). ^∗^*p* \< 0.05 vs. control group (G1), ^∗∗^*p* \< 0.05 vs. curcumin control group (G2), and ^∗∗∗^*p* \< 0.05 vs. AFB1 group (G3). Treatments represented as (G1) control group: fed only basal diet, (G2) curcumin control group: basal diet + 450 mg curcumin/kg feed, (G3) AFB~1~ group: basal diet + 5.0 mg AFB~1~/kg feed, and (G4) curcumin+AFB~1~ group: basal diet + 5.0 mg AFB~1~ + 450 mg curcumin/kg feed.](fphar-09-00554-g002){#F2}

Inhibition of Phase-I Enzymes
-----------------------------

The effect of curcumin, AFB~1,~ and curcumin+AFB~1~ diet was investigated at the mRNA and protein level. **Figure [3](#F3){ref-type="fig"}** shows four major CYP enzymes (CYP1A1, CYP1A2, CYP3A4, and CYP2A6) mRNA expression levels. Compared to control (**Figure [3](#F3){ref-type="fig"}**; G1) and curcumin control group (**Figure [3](#F3){ref-type="fig"}**; G2), AFB~1~ (**Figure [3](#F3){ref-type="fig"}**; G3) significantly (*p* \< 0.05) upregulated the mRNA expression level of the four CYP enzymes. However, curcumin supplementation (**Figure [3](#F3){ref-type="fig"}**; G4) in diet significantly (*p* \< 0.05) down-regulated AFB~1~-induced increase in CYP enzymes. Protein expression levels (**Figure [4](#F4){ref-type="fig"}**) showed the same trends as mRNA expression levels. Compared to control (**Figure [4](#F4){ref-type="fig"}**; G1) and curcumin control group (**Figure [4](#F4){ref-type="fig"}**; G2), a significant (*p* \< 0.05) increase has been noted in all CYP enzyme protein levels in AFB~1~-fed group (**Figure [4](#F4){ref-type="fig"}**; G3). While curcumin supplementation (**Figure [4](#F4){ref-type="fig"}**; G4) significantly (*p* \< 0.05) decreased the protein expression levels of CYP1A1, CYP1A2 and CYP3A4, the decrease is not statistically significant for CYP2A6 (*p* \> 0.05) protein expression. The data clearly showed that CYP1A1, CYP1A2, CYP3A4 and CYP2A6 actively involved in AFB~1~ bioactivation. However, curcumin supplementation significantly down-regulated the expression level of these enzymes at mRNA and protein level, and hence inhibited CYP enzymes-mediated bioactivation of AFB~1~.

![Figure shows the liver mRNA expression of CYP1A1, CYP1A2, CYP3A4, and CYP2A6 enzyme of the four treated groups. The values are represented as mean ± SE (*n* = 3). Treatments represented as (G1) control group: fed only basal diet, (G2) curcumin control group: basal diet + 450 mg curcumin/kg feed, (G3) AFB~1~ group: basal diet + 5.0 mg AFB~1~/kg feed, and (G4) curcumin+AFB~1~ group: basal diet + 5.0 mg AFB~1~ + 450 mg curcumin/kg feed. The value of *P* \< 0.05 was considered statistically significant. ^∗^*p* \< 0.05 vs. control group (G1), ^∗∗^*p* \< 0.05 vs. curcumin control group (G2) and ^∗∗∗^*p* \< 0.05 vs. AFB1 group (G3).](fphar-09-00554-g003){#F3}

![Western blot analysis of CYP enzymes involved in AFB~1~-bioactivation. CYP1A1, CYP1A2, CYP3A4, and CYP2A6 protein expression level of the four treated groups shown in the figure. The intensity of the protein bands was quantified by densitometry analysis. The levels of beta-actin were used as internal standard control. The values represented as mean ± SE (*n* = 3). Treatments represented as (G1) control group: fed only basal diet, (G2) curcumin control group: basal diet + 450 mg curcumin/kg feed, (G3) AFB~1~ group: basal diet + 5.0 mg AFB~1~/kg feed and (G4) curcumin+AFB~1~ group: basal diet + 5.0 mg AFB~1~ + 450 mg curcumin/kg feed. The value of *P* \< 0.05 was considered statistically significant. ^∗^*p* \< 0.05 vs. control group (G1), ^∗∗^*p* \< 0.05 vs. curcumin control group (G2) and ^∗∗∗^*p* \< 0.05 vs. AFB1 group (G3).](fphar-09-00554-g004){#F4}

Curcumin Induced the Transcriptional Activation of Nrf2 and Phase-II Enzymes
----------------------------------------------------------------------------

It is well understood that Nrf2 plays a crucial role in the defense system of a body and is an important regulator of several cellular pathways including phase-II enzymes involved in the detoxification of AFB~1~. Here, we examined the changes induced by diets supplemented with AFB~1~ and curcumin alone or in combination on Nrf2, GSTA3, and GSTM2 at mRNA and protein level. The mRNA expression level of Nrf2, GSTA3, and GSTM2 are displayed in **Figure [5](#F5){ref-type="fig"}**. Compared to control (**Figure [5](#F5){ref-type="fig"}**; G1) and curcumin control group (**Figure [5](#F5){ref-type="fig"}**; G2), AFB~1~ (**Figure [5](#F5){ref-type="fig"}**; G3) significantly (*p* \< 0.05) down-regulated Nrf2, GSTA3, and GSTM2 mRNA expression level. Interestingly, curcumin significantly (*p* \< 0.05) enhanced AFB~1~-induced decrease in Nrf2, GSTA3, and GSTM2 mRNA expression level (**Figure [5](#F5){ref-type="fig"}**; G4). Similar trends were observed in Nrf2, GSTA3, and GSTM2 protein expression level (**Figure [6A](#F6){ref-type="fig"}**). Notably, Nrf2, GSTA3, and GSTM2 protein expression level has been significantly (*p* \< 0.05) reduced in AFB~1~-fed group (**Figure [6A](#F6){ref-type="fig"}**; G3) relative to control (**Figure [6A](#F6){ref-type="fig"}**; G1) and curcumin control group (**Figure [6A](#F6){ref-type="fig"}**; G2). On the other hand, curcumin supplemented diet (**Figure [6A](#F6){ref-type="fig"}**; G4) significantly (*p* \< 0.05) restored AFB~1~-induced decrease in Nrf2 and GSTA3, protein level. However, the increase in GSTM2 (**Figure [6A](#F6){ref-type="fig"}**; G4) is not statistically significant relative to AFB~1~-fed group (**Figure [6A](#F6){ref-type="fig"}**; G3). The data showed that curcumin significantly upregulated the transcription factor Nrf2 and subsequently its downstream genes such as phase-II enzymes (GSTA3, and GSTM2), and thus improves the defense system against AFB~1~-induced toxicity.

![Nrf2, GSTA3, and GSTM2 mRNA expression level of the four treated groups shown in the figure. Treatments represented as (G1) control group: fed only basal diet, (G2) curcumin control group: basal diet + 450 mg curcumin/kg feed, (G3) AFB~1~ group: basal diet + 5.0 mg AFB~1~/kg feed and (G4) curcumin+AFB~1~ group: basal diet + 5.0 mg AFB~1~ + 450 mg curcumin/kg feed. The values represented as mean ± SE (*n* = 3). The value of *P* \< 0.05 was considered statistically significant. ^∗^*p* \< 0.05 vs. control group (G1), ^∗∗^*p* \< 0.05 vs. curcumin control group (G2) and ^∗∗∗^*p* \< 0.05 vs. AFB1 group (G3).](fphar-09-00554-g005){#F5}

![Western blot analysis of Nrf2, GSTA3, and GSTM2 involved in AFB~1~-detoxification. **(A)** Nrf2, GSTA3, and GSTM2 protein expression level of the four treated groups shown. The intensity of the protein bands was quantified by densitometry analysis. The levels of GAPDH gene were used as internal standard control. The values represented as mean ± SE (*n* = 3). **(B)** Cytosolic GST enzyme activity (U/mg protein) of the four treated groups presented in the figure. Treatments represented as (G1) control group: fed only basal diet, (G2) curcumin control group: basal diet + 450 mg curcumin/kg feed, (G3) AFB~1~ group: basal diet + 5.0 mg AFB~1~/kg feed and (G4) curcumin+AFB~1~ group: basal diet + 5.0 mg AFB~1~ + 450 mg curcumin/kg feed. The value of *P* \< 0.05 was considered statistically significant. ^∗^*p* \< 0.05 vs. control group (G1), ^∗∗^*p* \< 0.05 vs. curcumin control group (G2) and ^∗∗∗^*p* \< 0.05 vs. AFB1 group (G3).](fphar-09-00554-g006){#F6}

Hepatic GST Enzyme Activity
---------------------------

GST enzymes play an important role in the detoxification (conjugation) of AFB~1~ metabolites. **Figure [6B](#F6){ref-type="fig"}** displays GST enzyme activity detected in liver cytosol. It has been noted that AFB~1~-supplemented diet (G3) significantly (*p* \< 0.05) reduced GST enzyme activity compared to control group (**Figure [6B](#F6){ref-type="fig"}**; G1) and curcumin control group (**Figure [6B](#F6){ref-type="fig"}**; G2). However, GST activity was markedly (*p* \< 0.05) elevated in curcumin+AFB~1~-fed group (**Figure [6B](#F6){ref-type="fig"}**; G4) relative to AFB~1~-fed group (**Figure [6B](#F6){ref-type="fig"}**; G3). These findings showed that curcumin actively increased GST enzyme activity to catalyze the harmful metabolites of AFB~1~.

Discussion
==========

Numerous studies reported that AFB~1~ is a well-known hepatotoxic and hepatocarcinogen and affects many systems at a time ([@B47]). The current study showed that AFB~1~ significantly modulated serum biochemical parameters. Liver histological observations showed abnormal morphological signs in AFB~1~-treated group, while oxidative stress parameters clearly revealed that AFB~1~ induced oxidative stress in hepatocytes. Liver weight markedly increased and body weight was significantly suppressed in the current study in AFB~1~-fed group. These abnormal findings related to AFB~1~ toxicity were in general agreement with previous studies ([@B32]; [@B25]; [@B15]; [@B41]). Notably, our data showed that dietary supplementation of curcumin ameliorated AFB~1~-induced oxidative stress and reversed serum biochemical changes. AFB~1~-induced abnormal morphological signs in the liver partially disappear with curcumin treatment. The above findings were in agreement with some earlier reports that curcumin significantly mitigated AFB~1~-induced toxicity in broiler liver ([@B19], [@B20]). It has been reported earlier that CYP1A1, CYP1A2, CYP2A6, and CYP3A4 are responsible for the bioactivation of AFB~1~ in poultry species (ducks, quails, turkeys and chickens) ([@B12],[@B13]). In this study, liver CYP1A1, CYP1A2, CYP3A4, and CYP2A6 were significantly upregulated in AFB~1~-fed group showing its involvement in AFB~1~ biotransformation into harmful metabolites. Interestingly, the inhibition of these enzymes may be a promising treatment to prevent AFB~1~-induced liver toxicity. Importantly, the use of curcumin markedly reduced the mRNA and protein expression levels of the selected CYP enzymes in broiler liver *in vivo*. Our previous study demonstrated that curcumin inhibited CYP2A6 enzyme activity (in a dose dependent manner) involved in AFB~1~-bioactivation ([@B41]). [@B60] also reported that curcumin significantly inhibited CYP enzymes-mediated bioactivation of AFB~1~ into AFBO. Similarly, it has been noted that AFB~1~-induced increase expression of chicken CYP2H1 and CYP1A1 was alleviated with dietary curcumin ([@B58]). Moreover, curcumin attenuated Benzo\[a\]Pyrene-induced oxidative stress and reduced DNA adducts in mice via inhibiting CYP1A1/1A2 activities (*in vivo*) ([@B18]), decreased CYP3A activity in rats ([@B29]), and modulated CYP1A2, CYP3A4, CYP2B6, CYP2C9, and CYP2D6 activity in humans ([@B8]). Thus, curcumin could possibly prevent AFB~1~-induced hepatotoxicity though the synergistic effects of increased antioxidant capacities and inhibition of the cytochrome enzymes mediated activation to AFBO. However, the mechanism behind cytochrome P450 enzymes inhibition is still unknown and further molecular studies are needed to know the exact molecular mechanism of curcumin-mediated CYP450 inhibition.

Transcription factor Nrf2 is an attractive target in toxin chemoprevention due to its cytoprotective response and combat oxidative stress leading to prevention of DNA damage, carcinogenesis, and removal of toxic metabolites from the body ([@B52]). Previous reports demonstrated that curcumin is a potent inducer of Nrf2-pathway and its downstream genes involved in many cytoprotective mechanisms ([@B50]; [@B53]). Nrf2 plays a crucial role in chemoprevention and reduce liver injury via up-regulating GST enzymes responsible for the detoxification of AFB~1~ harmful metabolites such as AFBO ([@B45]), and meanwhile upregulate antioxidant defense system ([@B53]). The nuclear translocation of AFB~1~ is associated with many cellular proteins carrying signals for its translocation and subsequent binding to DNA, which results in DNA damage or causes deterioration of cellular proteins ([@B49]). Intriguingly, AFB~1~-induced impairment of specific protein functions or DNA damage decreased cell survival in cultured cells ([@B10]). Previous studies demonstrated that protein biosynthesis is weakened due to the formation of AFB~1~-DNA adducts. In addition, AFB~1~ could change the activity of enzymes such as cyclic nucleotide phosphodiesterase, protein kinase, and Ca^2+^-ATPase, alter hepatic protein phosphorylation ([@B40]; [@B49]), and causes p53 mutation which may develop carcinogenesis in experimental animals ([@B5]). Similarly, our data showed that Nrf2 mRNA and protein expression level significantly down-regulated in AFB~1~-fed group. Consequently, the downstream genes of Nrf2 such as GSTA3, and GSTM2 mRNA and protein expression levels markedly decreased in AFB~1~-fed group. Hence, it is speculated that the reduction in protein level could be due to AFB~1~-induced impairment in protein synthesis in broiler hepatocytes. Meanwhile, curcumin supplementation reversed AFB~1~-induced decrease in Nrf2, GSTA3, and GSTM2 mRNA and protein expression level. Furthermore, curcumin markedly increased GST enzyme activity involved in detoxification (conjugation) of AFB~1~. Similarly, previous studies reported that GST enzymes play a major role in prevention of AFB~1~-induced toxic effects and carcinogenesis ([@B33]), and could prevent AFB~1~-induced hepatic carcinoma in fisher F344 rats via Nrf2-pathway ([@B14]). We found that curcumin could inhibit cytochrome P450 enzymes-mediated bioactivation of AFB~1~ along with activation of Nrf2-pathway. In addition, our data showed that curcumin alleviated oxidative stress and caused alteration in AFB~1~-induced changes in serum biochemical parameters. These evidences suggested that curcumin could effectively inhibit AFB~1~-induced toxicity in broilers liver. Recently, many studies reported the chemopreventive effects of curcumin against AFB~1~-induced liver injury in several experimental animals ([@B33]; [@B19]; [@B58]; [@B45]; [@B60]). However, these studies only investigated the preventive effects of curcumin through phase-I enzymes or phase-II enzymes against AFB~1~-induced liver injury. In contrast, in this study, we scrutinized the multi-target effects of curcumin regulating both phase-I enzymes and phase-II enzymes via Nrf2-pathway involved in AFB~1~ bioactivation and detoxification. It has been noted from our previous study that 450 mg/kg curcumin provided maximum amelioration and significantly inhibited CYP2A6-mediated AFB~1~ bioactivation ([@B41]). Therefore, in this study, we selected the dose of curcumin (450 mg/kg feed) to explore its preventive effects against dietary AFB~1~ at a dose of 5 mg/kg feed. However, previous studies reported that curcumin is regarded a safe compound at a dose of 12 g/day ([@B9]), acts as anti-inflammatory, anti-tumor, and anti-oxidant, etc. ([@B1]), regulates pharmacological activities in a direct or indirect way and modulates various signaling molecules including cell survival proteins, apoptosis, drug resistance protein, etc. ([@B9]; [@B2]), and possess the ability to scavenge free radicals ([@B55]). Our data also showed that curcumin prevented liver dysfunction due to its anti-oxidant activity as well as modulating drug metabolizing enzymes including liver phase-I enzymes, Nrf2, and phase-II enzymes. In addition, higher studies are needed to investigate the preventive effects of curcumin and AFB~1~-induced undesirable changes in other cellular pathways such as cell cycle arrest, autophagy, apoptosis and cell death.

Conclusion
==========

In conclusion, we showed that dietary AFB~1~ negatively altered serum biochemical parameters, reduced activities of liver anti-oxidative enzymes, suppressed Nrf2 and phase-II enzymes involved in AFB~1~ detoxification, and markedly increased the expression level of CYP enzymes involved in AFB~1~ biotransformation, while dietary curcumin significantly reversed AFB~1~-induced alterations in serum biochemical parameters and enhanced liver antioxidant enzyme activities. Moreover, curcumin inhibited CYP enzymes-mediated bioactivation of AFB~1~ and upregulated Nrf2 defense system including GST enzyme activity. Therefore, the above novel findings suggested that dietary curcumin is recommended as a prophylactic measure to prevent AFB~1~-induced hepatocellular toxicity and oxidative stress.
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